BioPharma Resources

Drug Trial Radar · NCT02499562

A Phase II Clinical Trial of Hydronidone Capsules(F351) in Patients With Liver Fibrosis Induced by HBV Chronic Hepatitis

Randomed and Double-blinded Phase II Clinical Trial of Hydronidone Capsules(F351) in Patients With Liver Fibrosis Induced by HBV Chronic Hepatitis

Last checked: Nov 19, 2026Latest source record: Jun 23, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 168 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

168

Actual

Start

Jun 25, 2015

Primary completion

Nov 20, 2020

Study completion Nov 20, 2020

Sponsor

Lead sponsor
Shanghai Genomics, Inc.Industry
Sponsor type
Industry
First posted
Jul 16, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To explore the effective dose and safety of the effect of hydronidone and entecavir on hepatic fibrosis in chronic viral hepatitis B.

Conditions

  • Hepatitis B, Chronic

Interventions

  • HydronidoneDrug

    The investigational products in the test groups and control group shall be orally taken 30 minutes before meals for 52 continuous weeks. There are respectively 60 cases in the test group I, II, III and the control group, totally 240 cases.

  • PlaceboDrug

  • EntecavirDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes in hepatic fibrosis in chronic viral hepatitis BTime frame: one year

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Beijing, China

  • Shanghai General Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.